–ѕа°±б>ю€ ю€€€ю€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ l …бЅњјв\pThe Free Software Foundation BдЬ=PF0*8X@Н"ЈЏ1іР Helvetica1іРCourier1іР Courier New1іЉ Courier New1іР Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)ах€ ј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј а ј а+х€ шј а)х€ шј а,х€ шј а*х€ шј а х€ шј а –И ~~ња ЎИ ~~ња#ЎИ ~~ња"ЎИ ~~ња7#№И ~~ња ЎИ ~~ња8#№И ~~њУА€УА€УА€УА€УА€УА€Тв8€€€€€€€€€€€€АААААААААјјјАААЩЩ€Щ3f€€ћћ€€ff€ААfћћћ€А€€€€€€ААААА€ћ€ћ€€ћ€ћ€€ЩЩћ€€ЩћћЩ€€ћЩ3f€3ћћЩћ€ћ€Щ€fffЩЦЦЦ3f3Щf333Щ3Щ3f33Щ«««Е&Item 901 Financial Statements aЕ` SCHEDULE IЕt Exhibit 52 l … !mэ  dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?д SCHEDULE I Exhibit 52U } I } $ } U5 !ббббббббб б б б б бббббббббббббббббббTherapeuticsMD, Inc. 8-K 08/03/20185-Item 9.01. Financial Statements and Exhibits. Exhibit   Description Number   ЪЩЩЩЩЩс? / 'Underwriting Agreement, dated August 1,  4 ,2018, by and between the Company and Goldman1)Sachs & Co. LLC, as representative of the*"several underwriters named thereinffffff@.&Opinion of Greenberg Traurig, LLP (re:'Commission File No. 333-226452)Ќћћћћћ@.&Opinion of Greenberg Traurig, LLP (re:'Commission File No. 333-207837)ЪЩЩЩЩ7@.&Consent of Greenberg Traurig, LLP (setforth in Exhibit 5.1)3333337@.&Consent of Greenberg Traurig, LLP (setforth in Exhibit 5.2)$____________________________1)Created by Morningstar Document Research.„Dуlа€—€ї€ѓ€v€j€^€R€.€шюжюќю}ю-юаэЪэВэ2эпь„ьЗьDь,ь№ы£ыЛы;ыыцъкъ б0 (http://documentresearch.morningstar.com/„H=PF0*8X> ґ@е  l … З  dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?д!Item 901 Financial Statements a Exhibit 52U } U} $ } y} $ } y} $   б б б б б б б б б б б б б б б б б б б б б б б б б бTherapeuticsMD, Inc. 8-K 08/03/2018 SCHEDULE I  Underwriter   Number of   Maximum     Firm Shares    Number of   to be   Optional    Purchased   Shares       WhichMay be PurchasedGoldman Sachs & Co. LLC~ Nљ“~ ќFCantor Fitzgerald & Co.~ ё(7~ Жђ. Total~ *ж ~ Rѓt$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/„8Кфа€—€ї€ѓ€Щ€Н€Б€u€ €Ъю>юйэТэ9эяьВьыыtыыУъ'ъъъзщ=PF0*8X> ґ@еr          l … ы  dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?д!Item 901 Financial Statements a SCHEDULE IU } √1 ббббббббб б б б б ббббббTherapeuticsMD, Inc. 8-K 08/03/2018 Exhibit 5.2 Very truly yours, " /s/ Greenberg Traurig, LLP  Greenberg Traurig, LLP$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/„*:hа€—€ї€ѓ€Ш€М€А€t€h€K€?€€ €люяю”юЂю=PF0*8X> ґ@ Root Entry€€€€€€€€ јFю€€€Book €€€€€€€€€€€€ d! ю€€€ю€€€э€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€